Nature Reviews Cancer contents October 2014 Volume 14 Number 10 pp643-700

If you are unable to see the message below, click here to view.

Advertisement
The Science of Cancer Health Disparities in Racial/Ethnic Minorities Join us November 9-12 in San Antonio, TX. AACR Cancer Health Disparities conferences advance the understanding and help to eliminate the disparities in cancer that represent a major public health problem in our country.  Learn More.
TABLE OF CONTENTS
October 2014 Volume 14 Number 10
Impact Factor 37.912 *	In this issue Comment Research Highlights Reviews Perspectives Also this month Article series: Clinical insights  Featured article: DICER1: mutations, microRNAs and mechanisms William D. Foulkes, John R. Priest & Thomas F. Duchaine
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
nature.com webcasts Macmillan Science Communication presents a custom webcast on: An integrated OMICs approach to cancer progression Thursday October 23, 8am PDT, 11am EDT, 4pm BST, 5pm CEST Register for the webcast and live Q and A session   Sponsored by:
Article series: Clinical insights Comment: Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer Laura Ottini p643 | doi:10.1038/nrc3806 Ottini discusses what we understand about male breast cancer and what we can learn from it in terms of breast cancer pathogenesis. Abstract | Full Text | PDF
RESEARCH HIGHLIGHTS Top Metastasis: Working in groups p645 | doi:10.1038/nrc3823 Aceto et al. demonstrate that in mouse models of breast cancer, clusters of circulating tumour cells (CTCs) are oligoclonal and are substantially more likely to give rise to metastases than single CTCs. CTC clusters also correlate with reduced survival in patients with breast and prostate cancer. PDF Therapeutics: Protective packaging p646 | doi:10.1038/nrc3821 Administration of autologous gene-modified haematopoietic stem cells (HSCs) improves treatment tolerance and outcome in glioblastoma overexpressing methylguanine methyltransferase (MGMT) and treated with O6-benzylguanine and temozolomide. PDF Signalling: Hippo signalling arrests tetraploid cell growth p646 | doi:10.1038/nrc3824 Ganem et al. elucidate the mechanisms underlying cell cycle arrest in tetraploid cells in vitro and in vivo. PDF IN THE NEWS Two might not be better p646 | doi:10.1038/nrc3828 A study in JAMA has found that women with unilateral breast cancer who undergo double mastectomies do not have better outcomes than those who undergo lumpectomy followed by radiation. PDF Therapeutics: Gastric cancer gets a red carpet treatment p648 | doi:10.1038/nrc3825 Vagal innervation promotes tumorigenesis via WNT signalling mediated by muscarinic acetylcholine receptor 3 (M3R) in gastric cancer. Denervation, therefore, might represent a feasible strategy to control this disease. PDF Tumour suppressors: Notch blocks bladder tumorigenesis p648 | doi:10.1038/nrc3826 Rampias et al. show that Notch signalling is frequently inactivated in human bladder cancers and its loss can promote tumorigenesis in mice through suppressing transcription of phosphatases that normally function to inhibit ERK signalling and proliferation. PDF Therapeutics: Bacterial treatment for cancer p648 | doi:10.1038/nrc3827 A new study has shown that intratumoural injection of attenuated bacteria can reduce tumour volume. PDF IN BRIEF Tumorigenesis: LIN28 addiction | Imaging: Delivered to your door | Targeted therapies: Insights from exceptional responders | Genetics: Working in pairs | Metabolism: Repressing glycolysis | Computational modelling: A computational crystal ball | Breast cancer: Driving postpartum metastasis | Therapeutics: Disrupting an oncogenic relationship PDF Cancer JOBS of the week Postdoctoral Research in MicroRNAs & Cancer Eastern Virginia Medical School Faculty Position in Medicinal Chemistry for Cancer Drug Discovery St. Jude Children's Research Hospital (SJCRH) Postdoctoral fellow-Cancer Biology Wayne State University (WSU) School of Medicine/Karmanos Cancer Institute PhD positions at Laboratory of Molecular and Cellular Cancer Biology, BIU Bar-Ilan University Group leader in cancer research Institut for Cancer and Aging, Nice (IRCAN) + Cancer Center Antoine Lacassagne (CAL) More Science jobs from Cancer EVENT Development of Cancer Medicines 27.11.14 London, UK More science events from
Advertisement
Fluorescence is at your fingertips with ZOE™, a benchtop cell imager you control by touch screen. Features brightfield illumination and three fluorescent channels. Step out of the darkroom, see the light!
REVIEWS		Top
Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma Chris Jones & Suzanne J. Baker p651 | doi:10.1038/nrc3811 There has recently been a flurry of publications on the molecular and genetic basis of diffuse high-grade glioma, a devastating paediatric tumour. In this Review, Jones and Baker integrate these findings to provide new insight into this disease. In particular, the unique selective pressures driving the paediatric disease along with their associated mutations, potential molecular mechanisms and how this information could be harnessed therapeutically, are discussed. Abstract | Full Text | PDF
DICER1: mutations, microRNAs and mechanisms William D. Foulkes, John R. Priest & Thomas F. Duchaine p662 | doi:10.1038/nrc3802 Germline mutations in DICER1 can lead to DICER1 syndrome, which is characterized by the predisposition of various types of cancer in childhood and during early adulthood. Additionally, specific DICER1 mutations occur in tumours. This Review discusses germline and somatically-acquired DICER1 mutations and their effects on tumorigenesis. Abstract | Full Text | PDF | Supplementary information
CUX1, a haploinsufficient tumour suppressor gene overexpressed in advanced cancers Zubaidah M. Ramdzan & Alain Nepveu p673 | doi:10.1038/nrc3805 CUT-like homeobox 1 (CUX1) is a homeobox gene that is implicated in both tumour suppression and progression. What are the functions of the CUX1 protein, and how might the opposite roles of CUX1 in cancer protection and progression be explained? Abstract | Full Text | PDF
PERSPECTIVES		Top
OPINION Stem cell-based therapies for cancer treatment: separating hope from hype Daniel W. Stuckey & Khalid Shah p683 | doi:10.1038/nrc3798 This Opinion article considers the current status of stem cell-based treatments for cancer, such as the optimization of technologies to manipulate and deploy stem cells to target cancerous cells. It addresses safety concerns and discusses how the most promising preclinical studies might be translated into the clinic. Abstract | Full Text | PDF
OPINION Integrative oncology: really the best of both worlds? David H. Gorski p692 | doi:10.1038/nrc3822 'Integrative oncology', also known as complementary and alternative medicine (CAM), is being increasingly accepted in cancer care and research. This Opinion article aims to define what is meant by CAM in cancer and argues that the vast majority of these treatments are supported by little, if any, scientific evidence. Furthermore, it asks the questions: is there any harm in these treatments, and are there any potential benefits? Abstract | Full Text | PDF
Advertisement
The Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Nature Genetics, and Nature Reviews Cancer present: NUCLEAR REPROGRAMMING AND THE CANCER GENOME 2014 October 31- November 2, 2014 Ramada Plaza, Guangzhou, China  Click here for more information or to register for this conference today!
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2012 Journal Citation Report (Thomson Reuters, 2013)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2014 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.